Abbott Laboratories
- Industrie
- Medical Devices
- Bourse
- États-Unis
- Pays / Région
- USA
- Date d'introduction en bourse
- 13 janvier 1978
- Effectif
- 122 000
- Site web
- www.abbott.com
Fourchette de valorisation composite · prudent $70–$85 / raisonnable $90–$105 / optimiste $115–$135. À $104.49, Dans la fourchette de valeur intrinsèque raisonnable.
À la publication $88.38 (21 mai 2026)
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Historique
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois. Formerly known as Abbott Alkaloidal Company, it changed its name to Abbott Laboratories in 1915, and its IPO is dated January 13, 1978. By 2026 the company had achieved 54 consecutive years of dividend increases and 409 consecutive quarterly dividends. In the first quarter of 2026 (March 2026) Abbott completed its acquisition of Exact Sciences, entering oncology diagnostics, raising nearly USD 19.86B in new long-term debt to finance the deal.
Position dans le secteur
Abbott is a Healthcare-sector company in Medical Devices, operating in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In 2025 net sales were USD 44.328B (segment revenue: Medical Devices USD 21.387B, Diagnostics USD 8.937B, Nutrition USD 8.451B, Established Pharma USD 5.536B), with R&D of USD 2.942B (6.6%). It employs 122,000 people and operates across 160+ countries, holding an A+/Aa3 investment-grade rating. Key products include FreeStyle Libre (over 7 million users), Ensure, Glucerna, Similac and Alinity; competitors named are DexCom, Medtronic, Boston Scientific, BD, Danaher and Roche.
Pas encore d'analyse sur cette valeur dans votre langue.